Atypical antipsychotics are nowadays the most widely used drugs to treat schizophrenia and other psychosis. Unfortunately, some of them can cause major metabolic adverse effects, such as weight gain, dyslipidemia and type 2 diabetes. The underlying lipogenic mechanisms of the antipsychotic drugs are not known, but several studies have focused on a central effect in the hypothalamic control of appetite regulation and energy expenditure. In a functional convergent genomic approach we recently used a cellular model and demonstrated that orexigenic antipsychotics that induce weight gain activate the expression of lipid biosynthesis genes controlled by the sterol regulatory element-binding protein (SREBP) transcription factors. We therefore hypothesized that the major genes involved in the SREBP activation of fatty acids and cholesterol production (SREBF1, SREBF2, SCAP, INSIG1 and INSIG2) would be strong candidate genes for interindividual variation in drug-induced weight gain. We genotyped a total of 44 HapMap-selected tagging single nucleotide polymorphisms in a sample of 160 German patients with schizophrenia that had been monitored with respect to changes in body mass index during antipsychotic drug treatment. We found a strong association (P = 0.0003-0.00007) between three markers localized within or near the INSIG2 gene (rs17587100, rs10490624 and rs17047764) and antipsychotic-related weight gain. Our finding is supported by the recent involvement of the INSIG2 gene in obesity in the general population and implicates SREBP-controlled lipogenesis in drug-induced metabolic adverse effects.
Introduction
Antipsychotic drugs represent a cornerstone in the treatment of schizophrenia. Unfortunately, many atypical antipsychotics but also some typical drugs have recently been much criticized because of their propensity to cause a variety of metabolic adverse effects. These include dyslipidemia, weight gain, type 2 diabetes and the metabolic syndrome, [1] [2] [3] [4] [5] with consequent increased risk of cardiovascular disorders. 6, 7 In addition, the weight gain may reduce treatment compliance in patients that otherwise respond efficiently to treatment. Major research efforts have therefore been launched to better understand and prevent this problem. 6, 8 Various mechanisms underlying these drug-induced metabolic adverse effects have been proposed, most of them focused around the hypothalamic control of appetite regulation and energy expenditure modulated through histamine and serotonin receptors. An association between the affinity of antipsychotic drugs to histamine H1-and serotonin 5-HT2C receptors and their potency to induce weight gain was described. 9, 10 Furthermore, Kim et al. 11 observed that orexigenic antipsychotics (for example, clozapine and olanzapine) but not weight neutral drugs (for example, ziprasidone) activate the appetite-stimulating AMP-kinase in the hypothalamus through histamine H1 receptors.
The weight gain induced by antipsychotic drugs is highly variable among individuals, 12 and a twin study has provided evidence that the initial change in body mass index (BMI) during treatment with antipsychotics is more strongly correlated between monozygous twins as compared to same-sex sib pairs, 13 suggesting that genetic factors play a major role. Several pharmacogenetic studies have investigated the role of different plausible candidate genes in antipsychotic-mediated weight gain (for review, see Mü ller and Kennedy 14 and Chagnon 2006 15 ). Most of the reports have failed to identify predisposing factors, but a promoter variant (À759C/T) of the serotonin 5-HT2C receptor gene seems to be associated with weight gain in antipsychotic-treated patients in several populations, [16] [17] [18] [19] [20] although a subgroup of the cohort used in the present study failed to show association with this promoter variant. 21 In an attempt to search for alternative explanations, we have used a cellular model of cultured human glial and liver cells exposed to antipsychotics. We demonstrated that such drugs activate the sterol regulatory element-binding protein (SREBP) transcription factors, with subsequent transcriptional upregulation of downstream cholesterol and fatty acid biosynthesis. 22, 23 There were marked differences between the drugs, with clozapine and chlorpromazine being the most potent SREBP activators in a context of therapeutically relevant concentrations, whereas ziprasidone had minimal effect. 24 We therefore hypothesized that antipsychotic-induced stimulation of cellular lipogenesis could be involved in the increased risk of dyslipidemia and weight gain.
The SREBP transcription factors normally regulate the expression of a number of genes involved in biosynthesis and uptake of cholesterol, fatty acids, triglycerides and phospholipids. [25] [26] [27] [28] The SREBPs are synthesized in the endoplasmic reticulum (ER) where they reside and form a complex with the SREBPcleavage activating protein (SCAP) and the insulininduced gene (INSIG) proteins 29 (which has two different isoforms, INSIG1 and INSIG2). At low sterol levels, the SREBPs are released from the membrane, activated by cleavage 30 and translocated to the nucleus ( Figure 1 ) where they bind to the SRE in the promoter of numerous SREBP target genes, hence activating lipogenic gene expression There are two different SREBP isoforms, SREBP1 (with two splice variants, SREBP1a and -1c, both encoded by the SREBF1 gene) and SREBP2 (encoded by SREBF2 gene). The different SREBP isoforms overlap in function, but SREBP1c controls the expression of fatty acid biosynthesis genes, 31 SREBP2 mainly regulates cholesterol biosynthetic genes, 32 whereas SREBP1a regulates the expression of both cholesterol and fatty acid biosynthesis genes, with the later more efficiently activated. 33 Based on our demonstration of antipsychoticinduced transcriptional activation of the SREBP system and lipid biosynthesis in cultured human cells, we considered SREBF1, SREBF2, SCAP, INSIG1 and INSIG2 as promising candidate genes for studying interindividual variation in weight gain in patients treated with antipsychotic drugs. Interestingly, the SREBF1 and INSIG2 genes have recently been associated with obesity in several different populations. [34] [35] [36] The aim of this study was therefore to examine tagging single nucleotide polymorphisms (tagSNPs) in these five SREBP-linked genes in a sample of clozapine-treated patients with schizophrenia.
Materials and methods

Clinical sample and DNA extraction
We studied a total of 160 German patients (97 male and 63 female; 21.9±8.9 years (mean±s.d.); range Figure 1 Activation of cellular lipogenesis by the sterol regulatory element-binding protein (SREBP) transcription factor system. Cellular sterol levels control the SREBP transcription factor activity. The SREBPs (red) are synthesized as inactive precursors in the endoplasmic reticulum (ER), they reside in a complex with the SREBP-cleavage activating protein (SCAP) (green) and the insulin-induced gene (INSIG) (two different isoforms, INSIG1 and INSIG2) (light blue). In the presence of sterols an interaction between SCAP and INSIG retains the SCAP/SREBP complex in the ER. When sterol levels are low, SCAP undergoes a conformational change and is released from INSIG. SCAP assists the transport of the 120 kDa precursor SREBP to the Golgi apparatus as the initial step in SREBP activation, followed by a two-step proteolytic cleavage involving the Golgi-specific S1P and S2P proteases, thus releasing a 60-70 kDa transcriptionally active N-terminal domain. The mature transcriptionally active basic-helix-loop-helix (red hexagonal) is subsequently translocated to the nucleus where it activates expression of genes involved in cholesterol and fatty acid biosynthesis via binding to their SRE.
10-64 years) who met ICD-10 criteria for schizophrenia spectrum disorders; all of Central European origin. Patients were ascertained at the Department of Child and Adolescent Psychiatry and the Department of Psychiatry at the University of Marburg, for initiation of clozapine treatment. We have previously 21, 37, 38 reported on the characteristics of a subsample of patients included in the current study. Briefly, all patients were first time users of clozapine, of whom 98 had been treated with typical antipsychotics prior to the use of clozapine, 26 patients had been pretreated > 2 weeks with an atypical antipsychotic only, and 36 had been pretreated with both atypical and typical antipsychotics, the mean period of antipsychotic treatment prior to entry in the study was 2.7 ± 5.3 years (range 0.02-31 years). The mean clozapine dose was 285±121 mg per day (range 50-800 mg per day). BMI of each patient was measured just before initiation of clozapine treatment (BMI-2). In addition, BMI at the start of the first antipsychotic treatment (BMI-1) was obtained retrospectively through medical records, and a third BMI value (BMI-3) was measured prospectively 12 ± 1.2 weeks after initiation of clozapine treatment. We are aware of the problems inherent in investigations based on the analysis of medical records. Nevertheless, in the light of the restrictions attached to the use of clozapine and the personal responsibility of physicians, patients were carefully observed and clinical relevant data carefully noted. Mean BMI values were 21.3±3.2 (range 15.4-35.1), 23.5±3.8 (range 16.9-35.6) and 25.4 ± 3.8 (range 16.6-39.7) for the BMI-1, BMI-2 and BMI-3 recordings, respectively. Exclusion criteria were other medical or neurological disorders and pregnancy. All patients gave written informed consent; the study was approved by the ethics committee of the Philipps University of Marburg, Germany.
Marker selection and genotyping
The markers were selected using the phase II (Oct 05) version of HapMap (http://www.hapmap.org/cgi-perl/ gbrowse/gbrowse/hapmap_phaseI/). SNP genotype data for the CEPH (Utah residents with ancestry from northern and western Europe) were downloaded for the genomic region of each gene plus 10 
Data analysis
Genotyping results were analyzed using the Helix Tree software (Golden Helix: http://www.goldenhelix. com/index.jsp). Standard w 2 -test of independence was used to exclude any markers with deviation from the Hardy-Weinberg equilibrium. The remaining markers were analyzed as single markers for a linear regression where the values of BMI (BMI-1, -2 and -3) or the change in BMI (BMI-2 versus BMI-1, BMI-3 versus BMI-2, and BMI-1 versus BMI-3) were the outcome predicted by the genotypes. The nominal P-values given are uncorrected for multiple testing. An experiment-wide threshold was calculated using the method by Nyholt et al. 40 (http://fraser.qimr. edu.au/general/daleN/SNPSpDfraser/). In addition, single marker associations were analyzed similarly with the STATA for pc version 9.0 (StataCorp, USA) for a linear regression where the change in BMI (see above) was the outcome parameter predicted by the genotypes. The genotypes were given codes of 0, 1 and 2 for the co-dominant model; 0, 1 and 1 for the dominant model and 0, 0 and 1 for the recessive model.
We also calculated haplotype trend regression on two-and three-markers sliding window haplotypes, estimated using the expectation-maximization algorithm implemented in Helix Tree (1000 iterations), using sex, age and BMI-1 as co-variates, for the whole data set. In addition, for the INSIG2 markers haplotype trend regression, we calculated a permuted INSIG2 and antipsychotic-related weight gain S Le Hellard et al P-value based on 10 000 shuffles as implemented in Helix Tree Regression analysis module. This option shows the permuted P-value as the percentile of the permutation tests in which the P-value is less or equal to the observed P-value (which is included in the set of 10 000 shuffles). In order to avoid misleading results caused by multiple rare haplotypes, haplotypes with a frequency p5% were clumped together into one haplotype. The post hoc sample power was calculated with the STATA for pc version 9.0 (StataCorp, USA), where the sample size was 160, a = 0.05 and effect size was determined post hoc using the observed mean and standard deviation for each genotype at each marker position.
Results
Marker selection and genotyping
Fifty-two tagSNPs in SREBPF1, SREBF2, SCAP, INSIG1 and INSIG2 were selected using the HapMap CEPH data. One SNP assay failed on design and could not be replaced by any other HapMap SNP. The remaining tagSNPs were genotyped on a sample of 160 individuals. Five SNPs had genotyping success too low for analysis. Two SNPs (rs12623648 in INSIG2 and rs2413660 in SREBF1) were in Hardy-Weinberg disequilibrium (P < 0.001), probably due to an error in the selection of the markers as they both appeared to be located in repeat rich regions (the other markers were also checked and none were in repeat regions). One marker was monomorphic in our population. In addition, we genotyped by sequencing the SNP rs7566605, localized 10.034 kb from the start of INSIG2, which was reported recently to be associated with obesity in several populations. 35, 36, [41] [42] [43] [44] [45] [46] [47] [48] In total we analyzed 44 SNPs: 3 SNPs in INSIG1, 21 SNPs in INSIG2, 3 SNPs in SCAP, 4 SNPs in SREBF1 and 13 SNPs in SREBF2.
Association analysis
The sample of 160 clozapine-treated patients with schizophrenia had been characterized for their BMI at three time points: (1) BMI at the very first antipsychotic treatment (BMI-1), (2) BMI at the time of entry in the study just prior to the switch to clozapine treatment (BMI-2) and (3) BMI measured after an average of 12 weeks ( ± 1.2) on clozapine (BMI-3). We first performed single marker analysis with the Helix Tree software. We observed no association between the markers tested and weight before initiation of antipsychotic treatment (BMI-1). After antipsychotic treatment (BMI-2), we found a modest association with two markers in INSIG2: rs17587100 and rs10490624 (P-values 0.01 and 0.006, respectively). No marker showed association with BMI-3.
The data were then analyzed for association with mean change in BMI with a linear regression analysis using sex, age and BMI-1 as co-variates. The results of the single marker analysis along with the SNP information are displayed in Table 1 . We observed a highly significant association (P = 0.0003-P = 0.00007) between three markers localized within or near the INSIG2 gene (rs17587100, rs10490624, and rs17047764) and weight gain from the initiation of antipsychotic drug treatment (BMI-1) to the time of inclusion (BMI-2) (that is, the retrospectively recorded change in BMI); an additional two markers had P-values of 0.005 and 0.002. Three of these markers were also associated with weight gain under clozapine treatment (BMI-3 versus BMI-2, that is, prospective record), but the association was not as strong as for the BMI-1 versus BMI-2 difference (P = 0.003-0.04; see Table 1 ). Due to the remarkably low P-values, the results obtained initially with the Helix Tree software were double-checked by analyzing the data with STATA, which confirmed the strong association observed between the three markers located in INSIG2 and antipsychotic-induced weight gain (data not shown; available upon request). One INSIG2 marker (rs10490624) also demonstrated association with weight gain over the whole antipsychotic treatment period (BMI-1 versus BMI-3), although the P-values were lower than those seen in the first set (BMI-1 versus BMI-2).
We observed no significant association with the marker rs7566605 near INSIG2, which has been associated with obesity in several independent populations. The single marker analyses of the SREBF1, SREBF2, SCAP and INSIG1 genes turned out negative, except for three nominally significant SNPs, one in INSIG1 (rs13223383; P = 0.005) and one in SREBF2 (rs4822064; P = 0.04) with BMI-2 versus BMI-3, and one in SCAP (rs12490383; P = 0.01) with BMI-1 versus BMI-3 (Table 1) .
We performed a considerable number of tests in a total of five different genes, and although the Bonferroni correction is over-conservative (as many of the tests are correlated), the strongest associations observed still remain significant at the Bonferroni experience-wide threshold of P = 0.0011. The experiencewide threshold calculated with the Nyholt method, P = 0.0012, is actually very similar to the one obtained by Bonferroni method. This is expected if the selected markers are in low LD and it reflects that 41.3 out of the 43 markers are effectively independent (as calculated by the Nyholt method).
We calculated a post hoc power at each marker position under a dominant model for BMI changes (BMI-1 versus BMI-2 and BMI-2 versus BMI-3), using 160 for the sample size, a = 0.05, and the observed mean and standard deviation for each genotype to determine the effect size. Each marker was regarded as independent of the others. For the markers that were significantly associated with antipsychoticrelated weight gain (see above), the power ranged from 0.6 for rs17587100 to 0.9 for rs17047764 (BMI-2 versus BMI-3).
Haplotype analysis
The four markers associated at the single marker level showed some degree of LD (D 0 0.7-1) but the INSIG2 and antipsychotic-related weight gain S Le Hellard et al r 2 remained weak (0.1-0.5). We therefore chose to examine the data also at the haplotype level using a haplotype trend regression (HTR) analysis with sliding windows of two and three markers and antipsychotic-related weight gain between BMI-1 and BMI-2 (Table 2) , and between BMI-2 and BMI-3 (data not shown). Sex, age and BMI-1 were included as co-variates and we performed permutation analysis with 10 000 shuffles for the INSIG2 markers. No haplotype in the other genes (SREBF1, SREBF2, SCAP and INSIG1) showed significant association (data not shown). Table 2 summarizes the P-values observed in the sample in comparison to the permuted P-value obtained from the 10 000 shuffles for the weight gain between BMI-1 and BMI-2 with the INSIG2 markers. We observed significant association of two haplotype blocks in INSIG2 and antipsychotic-related increase in BMI. The first block included markers rs2161830, rs17587100 and rs4849676 in the two-markers sliding window HTR and extended to rs2422166 and rs12464355 in the three-markers sliding window HTR, although the association with these two later markers probably reflects the association with the other markers ( Table 2) . We imported the genotype data in Haploview to generate solid spine of LD blocks and observed that these five markers are part of a common block located in 5 0 of the transcription start of INSIG2 (Figure 2) . The second block included nine markers (rs2402492, rs2161829, rs889904, rs10490624, rs13409050, rs17047764, rs10207953, rs12151787 and rs11681903) under the two-markers sliding window HTR and extended to rs2113485 with the three-markers sliding window. However, considering how the P-value becomes less significant when this last marker is included in the HTR, as compared to the HTR with two-markers, it is likely that the last marker is beyond the limit of the haplotype block associated. Six out of these ten markers formed a haplotype block located between intron 3 and 3 0 UTR of INSIG2 (see Figure 2) . The additional four markers from this haplotype block were in weaker LD with the other markers. Interestingly, we also observed association between the prospectively observed clozapine-induced weight gain (BMI-3 versus BMI-2) and seven of the same markers as for BMI-1-BMI-2 but weaker (P-values 0.008-0.04; data not shown).
The effect of INSIG2 genotype on weight gain In the total sample, mean BMI values were 21.3±3.2 (range 15.4-35.1), 23.5 ± 3.8 (range 16.9-35.6) and 25.4 ± 3.8 (range 16.6-39.7) for the BMI-1, BMI-2 and BMI-3 recordings, respectively. The genotype distribution of the most significant weight gain-associated INSIG2 marker (rs17587100, A/C polymorphism; Table 1 ) was 84.8 % AA (N = 129), 14.4% AC (N = 22) and 0.8 % CC (N = 1). Interestingly, the mean increase in BMI (difference in BMI-1 versus BMI-2; DBMI-1-2) was 1.8 ± 2.3 for the AA carriers as compared to 4.1±3.9 for the AC heterozygotes (P = 6.6 Â 10 À8 ), which represents an actual weight gain of about 5.2 ± 6.6 kg and 11.8 ± 11.2 kg, respectively, for a person of 170 cm height (the CC individual had a DBMI-1-2 of 5.1). Among the 25% fraction of patients with the highest increase in BMI (N = 40; DBMI-1-2, range: 3.5-10.9), the genotype distribution was 67.5% AA (N = 27), 30% AC (N = 12) and 2.5% CC (N = 1), whereas the 25% subjects with the lowest increase in BMI (N = 40; DBMI-1-2, range: À2.2-0.28) displayed 87.5% AA (N = 35), and 12.5% AC (N = 5) genotypes.
Discussion
Here we demonstrate a highly significant association between several markers within two haplotype blocks in INSIG2 and weight gain during antipsychotic treatment in a German sample of patients with schizophrenia. The finding is supported by the fact that (1) this candidate gene was selected a priori by us due to its involvement in antipsychotic-induced SREBP-mediated activation of lipid biosynthesis in cultured cells, (2) the association was observed with several markers which are not in complete LD, (3) the association was found in both the retrospective and prospective recording of antipsychotic-related weight gain in the sample and (4) INSIG2 has recently been independently implicated as a susceptibility gene in obesity in several but not all populations (see below). The present study is founded on our recent observation that antipsychotic drugs stimulate the SREBP transcription factors in cultured human glial and liver cells, with subsequent transcriptional upregulation of downstream cholesterol and fatty acid biosynthesis. 22, 23 There are marked differences between the drugs, with clozapine and chlorpromazine being the most potent SREBP activators in a context of therapeutically relevant concentrations, whereas ziprasidone has minimal effect, 24 which matches the potency of these drugs to induce weight gain. INSIG2 was one of five selected candidate genes due to its involvement in the control of SREBP activation, and our present findings suggest that the INSIG2 gene polymorphisms could play a role in the interindividual variation in weight gain observed in patients treated with antipsychotic drugs.
The role of INSIG2 in drug-induced weight gain is supported by several studies. A common variant (rs7566605) upstream of INSIG2 was first reported by Herbert et al. 35 to be associated with adult and childhood obesity. This association has now been confirmed in five cohorts in a large scaled project by Lyon et al., 36 but lack of confirmation was observed in three cohorts from this study and in seven additional populations. [41] [42] [43] [44] [45] [46] [47] [48] Although the association of this SNP to obesity is not seen in all population it is likely that this marker reflects the effect of a nearby genetic factor in some populations. Our study was designed to examine specifically the five SREBP system genes and we therefore covered the genomic region more thoroughly than in the studies mentioned above (and below). The marker rs7566605 did not show association with any trait we analyzed.
A recent study by Skelly et al. 48 looked at the marker rs7566605 (located 10 kb from INSIG2) and 10 other nearby markers in the CATIE sample. 49 They observed a 'non-significant statistical trend' for association between rs7566605 and BMI in the antipsychotic-treated patients, whereas no association was seen with the other markers they typed. However, out of the 10 markers, only one (rs7589375) was closer to INSIG2 than rs7566605 (3 kb from INSIG2), and both markers are in weak LD (r 2 < 0.4) with the INSIG2 markers that we found to be associated with drug-related weight gain in the present study. It is therefore possible that the trend they observed reflects an association with other markers within INSIG2.
In the mouse, a high-density SNP analysis identified Insig2 as a strong candidate susceptibility gene for variation in total plasma cholesterol levels. 50 From a functional point of view, the two INSIG proteins are both located in the membrane of the ER, where they negatively regulate SREBP activity and cholesterol biosynthesis through their sterol-dependent binding to SCAP. 29 In contrast to INSIG1, INSIG2 is usually expressed at low levels and SREBP is not required for its expression. 51 It could be speculated that the different INSIG2 haplotypes are linked to variation in its level of expression, thereby affecting the SREBPmediated lipogenic potential of antipsychotic drugs in various patients.
The association observed by us was most pronounced for the retrospectively recorded increase in BMI (that is, from the very first use of antipsychotic drugs to the inclusion in the study) but was also clearly evident for the prospectively measured weight gain following clozapine therapy. This trend corroborates a recent report that most of the antipsychotic-induced weight gain is displayed in the first year of treatment, with much less increase during the next 7 years. 52 Still, it should be considered that the effect we observed at least in part is due to the influence of INSIG2 on weight gain itself, independent of drug treatment. In this context, the prospective data pertaining to the association for DBMI-2-3 most likely reflect the effect of medication and in particular clozapine. Other limitations in the present study are sample size, variability of the antipsychotics used in the first period and the length of this treatment. In terms of genetic association studies, the number of subjects is rather small, but still represents a comparably large sample for the specific phenotype. The association we report should therefore be valuable, novel information in understanding weight gain related to antipsychotic treatment. Further studies are now needed for replication purposes as well as to investigate the effect of INSIG2 allelic forms on the lipogenic response of cells to antipsychotic exposure. In addition, it would be interesting to see other prospective studies looking at the effect of INSIG2 polymorphisms on weight gain in populations that have not been treated with drugs.
